EPISODE · Oct 21, 2021 · 15 MIN
Optimal Dosing Strategies With Regorafenib and TAS-102 for Patients With Metastatic Colorectal Cancer
from Decera Clinical Education Oncology Podcast · host Kanwal Raghav MD MBBS, Rachel Riechelmann MD PhD
In this episode, Kanwal Raghav, MD, and Rachel Riechelmann, MD, PhD, discuss key data supporting contemporary dosing strategies with the later-line treatment options regorafenib and TAS-102 for patients with mCRC, with topics including:Individualizing therapyClinical data and experience informing optimal dosingKey adverse eventsPresenters:Kanwal Raghav, MD, MBBSAssociate Professor, Gastrointestinal Medical Oncology The University of Texas MD Anderson Cancer CenterHouston, TexasRachel Riechelmann, MD, PhDHead, Clinical Oncology DepartmentMedical OncologistAC Camargo Cancer Center Sao Paulo, Brazil Content based on an online CME program supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.Link to full program: https://bit.ly/3aVXplL Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Embed this episode
What this episode covers
Listen to Kanwal Raghav, MD, and Rachel Riechelmann, MD, PhD, as they provide their clinical insights into dosing of key later-line treatment options for patients with mCRC.
NOW PLAYING
Optimal Dosing Strategies With Regorafenib and TAS-102 for Patients With Metastatic Colorectal Cancer
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.